Table 2 The comparison of neoadjuvant therapeutic response to clinicopathological findings
Treatment group | |||
|---|---|---|---|
Characteristics | NAC (27) | NACRT (28) | p value |
Median follow-up period of RFS | 47.0 | 32.5 | p = 0.23* |
Median follow-up period of OS | 51.0 | 35.0 | p = 0.23* |
Normalization of CEA value post NAT (yes), n (%) | 7 (54%) | 8 (50%) | p = 0.57* |
Distance from anal verge after NAT (< 5 cm), n (%) | 15 (56%) | 14 (50%) | p = 0.79 |
Pathological response (responder), n (%) | 9 (33%) | 13 (46%) | p = 0.23 |
*Complete response | 1 (3.7%) | 5 (18%) | |
Circumferential margin (negative), n (%) | 26 (93%) | 26 (93%) | p = 0.51 |
Lymphovascular invasion (present), n (%) | 15 (56%) | 13 (46%) | p = 0.34 |
ypT stage (ypT0–2), n (%) | 11 (41%) | 12 (43%) | p = 0.55 |
ypN (absent), n (%) | 21 (78%) | 21 (75%) | p = 0.53 |
Lymph node yield, n (%) | |||
Less than 12 | 7 (26%) | 19 (68%) | p = 0.002 |
12 or more | 20 (74%) | 9 (32%) | |
pLPLN (present), n (%) | 1/9 (11%) | 0/5 | p = 0.95 |
ypStage, n (%) | |||
ypStage0 (CR) | 1 (3.7%) | 4 (14%) | p = 0.59 |
ypStage1 | 7 (26%) | 6 (21%) | |
ypStage2 | 13 (48%) | 12 (43%) | |
ypStage3 | 6 (22%) | 6 (22%) | |